Gapping up
In reaction to strong earnings/guidance:
- MU +8.8%, RAD +4%, NKE +3.6%,
Other news:
- IMV +8.6% (announces finalization of the basket clinical study in collaboration with Merck (MRK) and reveals promising top line data from the bladder and MSI-High Cohorts)
- TMST +3.2% (authorizes share repurchase program for up to $50 mln of common stock; Board of Directors also approves 2022 capital expenditure budget for $40 mln)
- FTAI +2.7% (submitted documentation with respect to potential spin-off of infrastructure business)
- NKLA +2.6% (confirms settlement agreement with SEC)
- PROG +2.5% (completes exit from laboratory business through asset sale to Northwest Pathology)
- FSR +2% (partners with Bridgestone (BRDCY) for comprehensive after-sales and related maintenance solutions in France and Germany)
- HAYW +1.6% (approved new $450 mln stock repurchase program)
- LLY +1.5% (lebrikizumab demonstrated significant skin improvement and itch relief when combined with topical corticosteroids in people with atopic dermatitis in third Phase 3 study)
- SNY +1.1% (to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics)
- BA +1% (awarded $330 mln Air Force contract)
- NVS +1% (Sandoz submits Biologics License Application for proposed biosimilar trastuzumab to US FDA)
Analyst comments:
- PTEN +5.3% (upgraded to Overweight from Neutral at Piper Sandler)
- WEJO +5.3% (initiated with an Outperform at Wedbush)
- MKFG +5.2% (initiated with a Buy at Goldman)
- KLAC +4.4% (upgraded to Overweight from Equal Weight at Wells Fargo)
- VUZI +3.6% ( initiated with a Buy at Dawson James)
- HIPO +2.6% (initiated with an Overweight at Morgan Stanley)
- RMD +1.2% (upgraded to Overweight from Sector Weight at KeyBanc),